Tendonitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy (Therapy, Surgery), By Condition (Tennis Elbow, Golfer’s Elbow, Pitcher’s Elbow, Jumper’s Knee, Others), By Region and Competition, 2020-2030F

Market Overview

Global Tendonitis Treatment Market was valued at USD 231.51 billion in 2024 and is expected to reach USD 284.12 billion by 2030 with a CAGR of 3.47% during the forecast period. The global market for Tendonitis Treatment is experiencing significant growth, driven by the increasing incidence of bone related injuries among the aging population due to osteoporosis or weak bone. Additionally, the growing demand for the best treatment with a low cost along with increasing awareness about new therapies such as joint manipulation and physical therapy which will significantly increase the demand for tendonitis treatment across different parts of the globe.

Additionally, the growing improvement of healthcare infrastructure for the treatment of bone disorder across the globe is further expected to increase the demand for tendonitis treatment, thereby fuelling market growth. Besides, growing awareness about maintaining a healthy lifestyle people are looking for sports activities which will further expect to support the tendonitis treatment market growth during the forecast period. Furthermore, an increased number of sport-related injuries due to either trauma or overuse of muscles or joints, improper rehabilitation, and imbalanced training sessions is further expected to increase the demand for tendonitis treatment, thereby supporting market growth. According to the National Safety Council (NSC), in 2021, exercise equipment accounted for about 409,000 injuries, the most in any category of sports and recreation.

Key Market Drivers

Aging Population & Chronic Musculoskeletal Conditions

One of the primary forces fueling growth in tendonitis management is the rapidly aging global population, which leads to greater prevalence of chronic musculoskeletal conditions. Tendons naturally lose elasticity and strength with age, increasing susceptibility to injury. As a result, older adults frequently experience degenerative tendon issues—including rotator cuff tendinitis, Achilles tendonitis, and lateral epicondylitis. This demographic trend is well-documented by the WHO: approximately 1.71 billion people suffered from musculoskeletal disorders in 2021, a category commonly involving tendon-related injuries. In the U.S., shoulder tendonitis (rotator cuff) is the most common cause of shoulder pain in adults over 40, accounting for more than 70% of shoulder complaints. Furthermore, lateral epicondylitis (tennis elbow) impacts around 4–7% of the general population annually.

Governments are taking notes. For instance, Canada and the U.K. have invested in eldercare health initiatives which include reimbursement frameworks for outpatient rehabilitation and physiotherapy. In the U.S., Medicare covers physical therapy sessions essential for treating chronic tendonitis. These policy supports ensure that aging patients receive early intervention, helping ease pain, maintain mobility, and delay or avoid surgical procedures. As chronic tendon injuries create significant public health burdens—limiting mobility, increasing fall risk, and reducing quality of life—governments are actively promoting preventive and conservative care strategies. This aligns perfectly with the capabilities of tendonitis treatments, especially physical therapy, rehabilitation, and minimally invasive interventions. The result is strong demand for effective treatment modalities and widespread adoption globally.

Surge in Sports and Occupational-Related Injuries

A second key driver of the tendonitis treatment market is the increase in sports-related injuries and repetitive occupational strain, particularly among both athletes and workers in repetitive-motion roles. According to WHO data, tendonitis contributes to about 30% of all sports-related musculoskeletal injuries. Among runners, Achilles tendonitis affects nearly 10%, while office workers report wrist tendonitis—such as De Quervain’s tenosynovitis—at 10–15%. Occupational studies reveal prevalence up to 18–41% in workers with repetitive tasks, like miners and surgical staff. These injuries not only lead to personal discomfort and impaired ability but also substantial economic costs—from lost productivity to healthcare expenditures.

Governments worldwide are responding with occupational health regulations. For example, the European Agency for Safety and Health at Work recommends ergonomic workstations and regular stretching programs to prevent tendonitis. In Japan, workplace health guidelines mandate periodic breaks and stretching exercises to reduce cumulative tendon injury risks. Parallel increases in sport participation—driven by public health campaigns promoting active living—also contribute to tendon overload. Policies advocating safe sports engagement through education, regulations, and sports infrastructure indirectly support demand for rehabilitation services. This rise in both sports- and work-related tendon injuries is thereby fueling treatment adoption, particularly in rehabilitative and minimally invasive care.

Download Free Sample Report

Key Market Challenges

Limited Access & Reimbursement Barriers

Despite clear clinical need, uneven access to treatment and reimbursement limitations represents a significant obstacle in the tendonitis market, especially in low- and middle-income countries (LMICs). While conservative interventions like physical therapy, PRP injections, and ultrasound therapy are clinically proven, they often require recurrent clinic visits and specialized equipment, which may not be covered by insurance. In many countries, rehabilitation services are not included under universal health coverage or are subject to significant co-pays. WHO data indicates that over 50% of healthcare facilities in low-income nations lack basic rehab services, making early intervention rare. In LMICs, physical therapy is often limited to major cities, leaving many working adults and athletes unable to access standard tendonitis care.

Even in high-income countries, distribution of services is uneven, with rural and underserved areas facing shortages of PTs and sports medicine specialists. Without equitable reimbursement systems or incentives to improve infrastructure, gaps in tendonitis management persist—leading to delayed diagnosis, chronic conditions, and greater long-term costs.

High Cost & Uptake of Advanced/Regenerative Therapies

Another emerging challenge is the cost and uncertain long-term evidence of advanced regenerative therapies, such as PRP (platelet-rich plasma), stem-cell injections, and biologic agents. While offering promising outcomes, these treatments can cost anywhere from USD 500 to over USD 10,000 per session, and routine insurance coverage is almost nonexistent.

This cost barrier is compounded by varying levels of institutional acceptance. In the U.S., Medicare and many insurers classify these interventions as "experimental" or off-label, requiring out-of-pocket payments. Government bodies in Germany and Japan are carefully evaluating clinical evidence before including coverage for regenerative therapies, while regulatory processes for evaluating such treatments still lack clarity.

The financial inaccessibility and mixed scientific evidence hinder widespread adoption. Patients and providers are often reluctant to invest in expensive treatments without guaranteed outcomes. Unless governments establish clear guidelines—covering reimbursement policies and clinical efficacy—advanced biological therapies will remain niche, especially in publicly funded health systems.

Key Market Trends

Growth of Tele-Rehabilitation & Digital Health Tools

An important trend redefining tendonitis care is the expansion of tele-rehabilitation and digital health platforms. Driven by the need for remote and accessible healthcare—further accelerated during the COVID-19 pandemic—digital solutions now allow patients to receive physical therapy and guided exercise programs via video consultations and mobile apps. Governments are supporting this transformation. In the U.S., the Centers for Medicare & Medicaid Services (CMS) expanded telehealth reimbursement policies during the pandemic and are evaluating permanent inclusion of remote physical therapy services. Many EU countries now fund telerehab to overcome rural care disparities, while Australia reimburses remote physiotherapy under Medicare.

Digital platforms often include exercise instruction, progression tracking, and wearables that monitor movement patterns—enabling clinicians to assess patients' function remotely and tailor therapy accordingly. This model enables early intervention, continuous monitoring, and improved adherence, which are especially valuable when clinical access is limited or travel is difficult. The convergence of telemedicine reimbursement and technology advances is transforming tendonitis treatment—making care more scalable, cost-effective, and patient-centered.

Rise in Evidence-Based Protocols: Eccentric Loading & Shockwave Therapy

A second influential trend is the shift toward evidence-based, non-surgical protocols—notably eccentric exercise regimens and extracorporeal shockwave therapy (ESWT)backed by strong clinical guidelines and government health bodies. High-quality systematic reviews identify eccentric loading exercises (e.g. for Achilles and patellar tendinopathy) as the gold standard for conservative management. National health authorities, including the National Institute for Health and Care Excellence (NICE) in the UK, now include eccentric loading as first-line treatment in their tendonitis guidelines. In Canada and Australia, accredited physiotherapy frameworks mandate structured resistance exercise programs as standard care for tendon injuries.

Further, moderate-evidence support exists for low-energy extracorporeal shockwave therapy, which is covered by public health systems in several European countries. These protocols offer highly reproducible results, fewer side effects, and well-documented cost-effectiveness—reducing the need for surgery or injections in many cases. As these evidence-based interventions gain traction among payers and providers, care is increasingly standardized, boosting the demand for physiotherapy-led treatment models and minimally invasive technologies aligned with conservative management principles.

Segmental Insights

Therapy Insights

Based on Therapy, the therapy category holds the largest market share compared to surgical interventions. This dominance is primarily due to the widespread preference for non-invasive or minimally invasive approaches as the first line of treatment for tendonitis, particularly in mild to moderate cases. Therapy options typically include physical therapy, rest, ice application, compression, elevation (RICE), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, and more recently, regenerative therapies like Platelet-Rich Plasma (PRP) and stem cell therapy. These modalities are effective in managing symptoms, reducing inflammation, and restoring functionality without the risks or recovery times associated with surgical procedures. Patients, especially in aging populations, often prefer non-surgical routes due to fewer complications and quicker recovery periods. Moreover, primary care physicians and orthopedic specialists usually recommend therapeutic interventions before considering surgical options. These treatments are not only more accessible but also more affordable, making them a viable solution across both developed and developing healthcare settings.

Download Free Sample Report

Regional Insights

Based on the region, North America holds the largest market share in the Global Tendonitis Treatment Market. This dominance can be attributed to a combination of factors including a well-established healthcare infrastructure, high awareness of musculoskeletal health, and widespread access to advanced diagnostic and therapeutic modalities. The region is home to a large aging population, particularly in the United States and Canada, where the prevalence of age-related tendon disorders like rotator cuff injuries and Achilles tendinopathy is significantly high. Additionally, the region has a large base of professional and amateur athletes, leading to a higher incidence of sports-related tendon injuries, which fuels demand for timely and effective tendonitis treatments. Government initiatives and insurance policies in countries like the U.S. further support the market. Medicare and private insurance providers often cover conservative treatments such as physical therapy, corticosteroid injections, and surgical interventions when necessary. Furthermore, North America leads in the adoption of advanced medical technologies, including regenerative therapies like platelet-rich plasma (PRP) and stem cell treatments, although some of these are still limited in coverage.

Recent Developments

• In November 2024, Johnson & Johnson MedTech, a global leader in orthopedic technologies, announced that it will present its extensive range of products and data-driven solutions at the American Association of Hip and Knee Surgeons (AAHKS) 2024 Annual Meeting in Dallas.
• In July 2024, Anika Therapeutics, Inc., a company in joint preservation focused on early intervention in orthopedics, announced the launch of its Integrity Implant System, which is widely available across the U.S. The Integrity System includes a hyaluronic acid-based implant, bone and tendon fixation components, and specialized single-use arthroscopic delivery instruments.
• In January 2024, Arthrex, a leader in minimally invasive surgery and surgical education, launched TheNanoExperience.com, a new resource focused on the benefits of Nano arthroscopy. This advanced, minimally invasive orthopedic procedure facilitates quicker recovery and reduces pain, allowing patients to return to activity sooner. The platform aims to educate patients on the science behind the procedure and its potential advantages.

Key Market Players

• Merck KGaA
• Bayer AG
• AstraZeneca Plc.
• Boehringer Ingelheim International GmbH
• Abbott Laboratories, Inc.
• Pfizer, Inc.
• GlaxoSmithKline PLC
• Almatica Pharma, Inc.
• Teva Pharmaceuticals Industries
• Johnson & Johnson

Report Scope:

In this report, the Global Tendonitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Tendonitis Treatment Market, By Therapy:

o   Therapy

o   Surgery

• Tendonitis Treatment Market, By Condition:

o   Tennis Elbow

o   Golfer’s Elbow

o   Pitcher’s Elbow

o   Jumper’s Knee

o   Others

• Tendonitis Treatment Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tendonitis Treatment Market.

Available Customizations:

Global Tendonitis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Tendonitis Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]